Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium, Inc. (Nasdaq: EQ) is a La Jolla, California–based clinical-stage biotechnology company that publicly describes its focus as developing novel therapies for severe autoimmune and inflammatory disorders. News about Equillium often centers on the progress of its lead candidate EQ504, an investigational aryl hydrocarbon receptor (AhR) modulator, and on corporate actions that support its development strategy.
Readers of this EQ news page can follow company announcements on clinical and preclinical plans for EQ504, including preparations for Phase 1 studies in ulcerative colitis and related gastrointestinal conditions, as well as potential applications in inflammatory lung or pulmonary diseases. Equillium’s press releases also highlight scientific and translational updates, such as key opinion leader events discussing AhR modulation, intestinal inflammation and the unmet medical need in ulcerative colitis.
In addition to pipeline news, Equillium regularly reports on financing transactions like private placements and at-the-market offerings, which it links to funding the development of EQ504 and extending its operating runway. Corporate governance and leadership updates, including changes in board composition, committee membership and senior roles, are disclosed through both SEC filings and news releases.
Another recurring topic in Equillium’s news flow is its cryptocurrency treasury reserve strategy, which the company has described as part of its broader financial and growth objectives. Updates in this area appear alongside information on cash resources, investment policy changes and strategic priorities.
Investors and observers can use this news feed to monitor Equillium’s clinical plans, scientific positioning around AhR modulation, capital-raising activities, Nasdaq listing developments and treasury strategy, all of which shape the company’s path as a clinical-stage biotech focused on immuno-inflammatory diseases.
Equillium (Nasdaq: EQ) announced that management will present at Oppenheimer’s 2026 Innovation on the Island event on Tuesday, April 28, 2026 at 7:50am AST.
Members of management will be available for investor meetings for registered attendees, providing an opportunity for investor engagement and company updates.
Equillium (Nasdaq: EQ) announced that preclinical data for EQ504 will be presented as posters at IMMUNOLOGY2026™, April 15-19 in Boston. Two posters focus on EQ504 as a potent AhR modulator promoting immune tolerance (IL-10/IL-22) and epithelial barrier repair.
Presentations occur April 16 (Poster 242; speaker 2:30-3:30 PM EDT) and April 18 (Poster 517; speaker 11:30 AM-12:30 PM EDT); posters will be posted on the company Presentations page after each session.
Equillium (Nasdaq: EQ) announced an inducement grant on April 1, 2026: the Compensation Committee awarded a nonstatutory stock option for 32,000 shares to a new employee under the company’s 2024 Inducement Plan.
The option’s exercise price equals $2.04 (closing price on April 1, 2026) and vests over four years: 25% after one year then monthly over 36 months, subject to continued service and plan terms.
Equillium (Nasdaq: EQ) reported fourth-quarter and full-year 2025 results and recent corporate and clinical highlights on March 25, 2026. Key points: no revenue in 2025 versus $41.1M in 2024; FY net loss $22.4M (−$0.39/share); cash and short-term investments $30.3M at Dec 31, 2025; completed a $35M private placement in March 2026 and an up to $50M financing in Aug 2025. Company plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026 with data expected ~six months later and expects cash runway into 2029.
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the 38th Annual Roth Conference for Growth Companies on March 23, 2026 at 8:30am PT. The company said members of management will also be available for investor meetings with conference registrants.
This presentation offers investors direct access to management and updates on corporate strategy and development plans.
Equillium (Nasdaq: EQ) entered a definitive securities purchase agreement with RA Capital Management to raise approximately $35 million gross through a PIPE announced March 13, 2026. The company will issue roughly 18.9 million shares (including pre-funded warrants) at about $1.854 per share.
Net proceeds are intended to advance clinical development of EQ504, support working capital and general corporate purposes, and are expected to extend the company’s cash runway into 2029. RA Capital received customary Form S-3 resale registration rights.
Equillium (Nasdaq: EQ) announced management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.
Members of management will also be available for investor meetings with registered conference attendees.
Equillium (Nasdaq: EQ) granted inducement stock options to two new employees on January 30, 2026 for an aggregate of 59,750 shares under its 2024 Inducement Plan. Each option has an exercise price of $1.42 (closing price on January 30, 2026) and vests over four years.
Vesting: 25% on the one-year anniversary, then monthly over 36 months, subject to continued service and plan/agreement terms.
Equillium (Nasdaq: EQ) announced management will participate in two investor conferences in early December 2025: the Piper Sandler 37th Annual Healthcare Conference on Dec 2, 2025 at 11:30 AM ET and the Evercore ISI 8th Annual Healthcare Conference on Dec 3, 2025 at 3:50 PM ET. Meetings will include fireside chats and 1x1 investor meetings.
Management is available for meetings with registered investors. Investors are invited to review the company corporate deck on the Events & Presentations page and the replay of the recent virtual KOL event discussing EQ504, an aryl hydrocarbon receptor modulator for ulcerative colitis.
Equillium (Nasdaq: EQ) reported third quarter 2025 results and an operational update on Nov 13, 2025. Key corporate actions include a private placement providing up to $50.0M in gross proceeds with an initial $30.0M tranche expected to fund operations through 2027. The company plans to initiate a Phase 1 study of oral, colon-targeted AhR modulator EQ504 in mid-2026 and hosted a KOL event highlighting AhR's role in ulcerative colitis.
Q3 2025 results: Revenue $0 (vs $12.2M in Q3 2024), R&D $1.3M (vs $9.6M), G&A $3.3M, Net loss $4.2M (or $(0.06) per share), and Cash $33.1M as of Sept 30, 2025.